
Nicolas Tsapis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8184089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mannosylation of budesonide palmitate nanoprodrugs for improved macrophage targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 112-120.	4.3	10
2	Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles. Drug Delivery and Translational Research, 2022, 12, 1270-1284.	5.8	26
3	In vitro evaluation of polymeric nanoparticles with a fluorine core for drug delivery triggered by focused ultrasound. Colloids and Surfaces B: Biointerfaces, 2021, 200, 111561.	5.0	11
4	Combining dexamethasone and TNF-α siRNA within the same nanoparticles to enhance anti-inflammatory effect. International Journal of Pharmaceutics, 2021, 598, 120381.	5.2	6
5	Tiny dexamethasone palmitate nanoparticles for intravitreal injection: Optimization and in vivo evaluation. International Journal of Pharmaceutics, 2021, 600, 120509.	5.2	4
6	Simulations of the Upper Critical Solution Temperature Behavior of Poly(ornithine- <i>co</i> -citrulline)s Using MARTINI-Based Coarse-Grained Force Fields. Journal of Chemical Theory and Computation, 2021, 17, 4499-4511.	5.3	2
7	Liposomes Loaded with Everolimus and Coated with Hyaluronic Acid: A Promising Approach for Lung Fibrosis. International Journal of Molecular Sciences, 2021, 22, 7743.	4.1	9
8	Tuning morphology of Pickering emulsions stabilised by biodegradable PLGA nanoparticles: How PLGA characteristics influence emulsion properties. Journal of Colloid and Interface Science, 2021, 595, 202-211.	9.4	20
9	Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. Advanced Drug Delivery Reviews, 2021, 175, 113809.	13.7	30
10	Stability, pharmacokinetics, and biodistribution in mice of the EPAC1 inhibitor (R)-CE3F4 entrapped in liposomes and lipid nanocapsules. International Journal of Pharmaceutics, 2021, 610, 121213.	5.2	0
11	Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound. Pharmaceutics, 2020, 12, 1125.	4.5	39
12	Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 114-120.	4.3	49
13	Use of Natural Products in Asthma Treatment. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-35.	1.2	43
14	Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1630.	6.1	17
15	High molecular weight hyaluronic acid decorated-liposome as targeted drug delivery system for fibrotic lung disorders. , 2020, , .		0
16	Pickering emulsions: Preparation processes, key parameters governing their properties and potential for pharmaceutical applications. Journal of Controlled Release, 2019, 309, 302-332.	9.9	250
17	The crucial role of macromolecular engineering, drug encapsulation and dilution on the thermoresponsiveness of UCST diblock copolymer nanoparticles used for hyperthermia. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 281-290.	4.3	13
18	Hyaluronic Acid–Decorated Liposomes as Innovative Targeted Delivery System for Lung Fibrotic Cells. Molecules, 2019, 24, 3291.	3.8	33

#	Article	IF	CITATIONS
19	Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization. Acta Biomaterialia, 2019, 87, 177-186.	8.3	30
20	Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. International Journal of Pharmaceutics, 2019, 559, 68-75.	5.2	46
21	Nanoscale Lipophilic Prodrugs of Dexamethasone with Enhanced Pharmacokinetics. Molecular Pharmaceutics, 2019, 16, 2999-3010.	4.6	19
22	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Letters, 2019, 456, 29-39.	7.2	41
23	Impact of Polylactide Fluorinated End-Group Lengths and Their Dynamics on Perfluorohexane Microcapsule Morphology. Macromolecules, 2019, 52, 2589-2596.	4.8	2
24	Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation. Nanotoxicology, 2019, 13, 606-622.	3.0	25
25	SAT0057â€INCREASED MICRORNA-155 IS ASSOCIATED WITH A SPECIFIC DEFECT OF ANTI-INFLAMMATORY M2 MACROPHAGES POLARIZATION BOTH IN HUMAN RHEUMATOID ARTHRITIS AND IN COLLAGEN-INDUCED-ARTHRITIS MICE. , 2019, , .		0
26	Empirical and Theoretical Characterization of the Diffusion Process of Different Gadolinium-Based Nanoparticles within the Brain Tissue after Ultrasound-Induced Permeabilization of the Blood-Brain Barrier. Contrast Media and Molecular Imaging, 2019, 2019, 1-13.	0.8	21
27	Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. Journal of Controlled Release, 2019, 296, 179-189.	9.9	70
28	Thermoresponsive polymer nanocarriers for biomedical applications. Advanced Drug Delivery Reviews, 2019, 138, 167-192.	13.7	256
29	Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 61-72.	2.4	49
30	Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins. , 2019, 2, 381-398.		2
31	Pyrazinoic acid-Poly(malic acid) biodegradable nanoconjugate for efficient intracellular delivery. Precision Nanomedicine, 2019, 2, 303-317.	0.8	4
32	HPLC Quantification of Dexamethasone Palmitate in Bronchoalveolar Lavage Fluid of Rat after Lung Delivery with Large Porous Particles. American Journal of Analytical Chemistry, 2019, 10, 404-414.	0.9	0
33	Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. Journal of Controlled Release, 2018, 271, 98-106.	9.9	102
34	Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach. International Journal of Pharmaceutics, 2018, 548, 740-746.	5.2	31
35	Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids. European Journal of Pharmaceutical Sciences, 2018, 113, 185-192.	4.0	18
36	PLA-PEG Nanoparticles Improve the Anti-Inflammatory Effect of Rosiglitazone on Macrophages by Enhancing Drug Uptake Compared to Free Rosiglitazone. Materials, 2018, 11, 1845.	2.9	26

#	Article	IF	CITATIONS
37	Bare and Sterically Stabilized PLGA Nanoparticles for the Stabilization of Pickering Emulsions. Langmuir, 2018, 34, 13935-13945.	3.5	34
38	Protection against Clostridium difficile infection in a hamster model by oral vaccination using flagellin FliC-loaded pectin beads. Vaccine, 2018, 36, 6017-6021.	3.8	8
39	Elucidating the role of surface chemistry on cationic phosphorus dendrimer–siRNA complexation. Nanoscale, 2018, 10, 10952-10962.	5.6	20
40	Comb-Like Fluorophilic-Lipophilic-Hydrophilic Polymers for Nanocapsules as Ultrasound Contrast Agents. Biomacromolecules, 2018, 19, 3244-3256.	5.4	18
41	Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy. European Journal of Pharmaceutical Sciences, 2017, 103, 27-35.	4.0	31
42	Wound healing effects of collagen-laminin dermal matrix impregnated with resveratrol loaded hyaluronic acid-DPPC microparticles in diabetic rats. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 17-27.	4.3	59
43	Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin. International Journal of Pharmaceutics, 2017, 525, 203-210.	5.2	90
44	Anti-Inflammatory Effect of Anti-TNF-α SiRNA Cationic Phosphorus Dendrimer Nanocomplexes Administered Intranasally in a Murine Acute Lung Injury Model. Biomacromolecules, 2017, 18, 2379-2388.	5.4	78
45	How should we plan the future of nanomedicine for cancer diagnosis and therapy?. International Journal of Pharmaceutics, 2017, 532, 657-659.	5.2	11
46	End-chain fluorination of polyesters favors perfluorooctyl bromide encapsulation into echogenic PEGylated nanocapsules. Polymer Chemistry, 2017, 8, 2559-2570.	3.9	14
47	Echogenicity enhancement by end-fluorinated polylactide perfluorohexane nanocapsules: Towards ultrasound-activable nanosystems. Acta Biomaterialia, 2017, 64, 313-322.	8.3	17
48	Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules. Journal of Controlled Release, 2017, 264, 219-227.	9.9	36
49	Polysaccharide-coated liposomes by post-insertion of a hyaluronan-lipid conjugate. Colloids and Surfaces B: Biointerfaces, 2017, 158, 119-126.	5.0	32
50	Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs. Nanomedicine, 2016, 11, 1865-1887.	3.3	35
51	Imaging Polymer Nanoparticles by Means of Transmission and Scanning Electron Microscopy Techniques. , 2016, , 205-219.		2
52	AFM Investigation of Liquid-Filled Polymer Microcapsules Elasticity. Langmuir, 2016, 32, 4610-4618.	3.5	19
53	Paclitaxel-loaded PEGylated nanocapsules of perfluorooctyl bromide as theranostic agents. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 136-144.	4.3	34
54	Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications. Journal of Controlled Release, 2016, 241, 144-163.	9.9	204

#	Article	IF	CITATIONS
55	Control of particle morphology in the spray drying of colloidal suspensions. Soft Matter, 2016, 12, 7435-7444.	2.7	98
56	Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. International Journal of Pharmaceutics, 2016, 514, 103-111.	5.2	34
57	PEGylated nanocapsules of perfluorooctyl bromide: Mechanism of formation, influence of polymer concentration on morphology and mechanical properties. Colloids and Surfaces B: Biointerfaces, 2016, 146, 762-769.	5.0	13
58	Pulmonary Surfactant Protein A-Mediated Enrichment of Surface-Decorated Polymeric Nanoparticles in Alveolar Macrophages. Molecular Pharmaceutics, 2016, 13, 4168-4178.	4.6	25
59	Surface-Modified Biodegradable Nanoparticles' Impact on Cytotoxicity and Inflammation Response on a Co-Culture of Lung Epithelial Cells and Human-Like Macrophages. Journal of Biomedical Nanotechnology, 2016, 12, 135-146.	1.1	21
60	Disintegration of nano-embedded microparticles after deposition on mucus: A mechanistic study. Colloids and Surfaces B: Biointerfaces, 2016, 139, 219-227.	5.0	34
61	Compared <i>in vivo</i> toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles. Nanotoxicology, 2016, 10, 292-302.	3.0	45
62	Hyaluronic acid for anticancer drug and nucleic acid delivery. Advanced Drug Delivery Reviews, 2016, 97, 204-236.	13.7	468
63	Pulmonary delivery of pyrazinamide-loaded large porous particles. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 241-250.	4.3	33
64	Properties of theranostic nanoparticles determined in suspension by ultrasonic spectroscopy. Physical Chemistry Chemical Physics, 2015, 17, 25483-25493.	2.8	8
65	Perfluorocarbon-loaded micro and nanosystems for medical imaging: A state of the art. Journal of Fluorine Chemistry, 2015, 171, 18-26.	1.7	48
66	Evaluation of characteristics and in vitro antioxidant properties of RSV loaded hyaluronic acid–DPPC microparticles as a wound healing system. Colloids and Surfaces B: Biointerfaces, 2015, 126, 50-57.	5.0	45
67	Focused ultrasound influence on calcein-loaded thermosensitive stealth liposomes. International Journal of Hyperthermia, 2015, 31, 349-358.	2.5	21
68	Pectin beads loaded with chitosan–iron microspheres for specific colonic adsorption of ciprofloxacin. Journal of Drug Delivery Science and Technology, 2015, 30, 494-500.	3.0	14
69	Novel drug delivery systems for actinides (uranium and plutonium) decontamination agents. Advanced Drug Delivery Reviews, 2015, 90, 40-54.	13.7	43
70	Pyrazinamide-loaded poly(lactide-co-glycolide) nanoparticles: Optimization by experimental design. Journal of Drug Delivery Science and Technology, 2015, 30, 384-390.	3.0	7
71	Ex Vivo Uranium Decontamination Efficiency on Wounded Skin and In Vitro Skin Toxicity of a Calixarene-Loaded Nanoemulsion. Journal of Pharmaceutical Sciences, 2015, 104, 2008-2017.	3.3	12
72	Supramolecular Organization and siRNA Binding of Hyaluronic Acid-Coated Lipoplexes for Targeted Delivery to the CD44 Receptor. Langmuir, 2015, 31, 11186-11194.	3.5	36

#	Article	IF	CITATIONS
73	Formulation and Pharmacokinetics of Thermosensitive Stealth® Liposomes Encapsulating 5-Fluorouracil. Pharmaceutical Research, 2015, 32, 1585-1603.	3.5	24
74	Surface coating mediates the toxicity of polymeric nanoparticles towards human-like macrophages. International Journal of Pharmaceutics, 2015, 482, 75-83.	5.2	110
75	Pulmonary drug delivery systems for tuberculosis treatment. International Journal of Pharmaceutics, 2015, 478, 517-529.	5.2	149
76	Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 30-39.	4.3	71
77	Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. Bioconjugate Chemistry, 2015, 26, 1307-1313.	3.6	145
78	Probing single-cell mechanics with picosecond ultrasonics. Ultrasonics, 2015, 56, 160-171.	3.9	32
79	Evaluation of Lung Toxicity of Biodegradable Nanoparticles. Advances in Delivery Science and Technology, 2015, , 689-732.	0.4	1
80	Texturing formulations for uranium skin decontamination. Pharmaceutical Development and Technology, 2014, 19, 692-701.	2.4	8
81	Nanocapsules of perfluorooctyl bromide for theranostics: from formulation to targeting. , 2014, , .		0
82	Influence of polymer end-chemistry on the morphology of perfluorohexane polymeric microcapsules intended as ultrasound contrast agents. International Journal of Pharmaceutics, 2014, 471, 10-17.	5.2	18
83	A microdevice for parallelized pulmonary permeability studies. Biomedical Microdevices, 2014, 16, 277-285.	2.8	10
84	RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: Influence of pre or post-functionalization on capsule morphology. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 170-177.	4.3	39
85	High-frequency (20 to 40 MHz) acoustic response of liquid-filled nanocapsules. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2014, 61, 5-15.	3.0	7
86	Stabilization and cellular delivery of chitosan–polyphosphate nanoparticles by incorporation of iron. Journal of Controlled Release, 2014, 194, 211-219.	9.9	22
87	Nanomedicine technology: current achievements and new trends. Clinical and Translational Imaging, 2014, 2, 77-87.	2.1	32
88	Lung Toxicity of Biodegradable Nanoparticles. Journal of Biomedical Nanotechnology, 2014, 10, 2852-2864.	1.1	25
89	Adsorption of Antisense Oligonucleotides Targeting Malarial Topoisomerase II on Cationic Nanoemulsions Optimized by a Full Factorial Design. Current Topics in Medicinal Chemistry, 2014, 14, 1161-1171.	2.1	7
90	Hyaluronic acid-coated liposomes for active targeting of gemcitabine. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 373-380.	4.3	123

#	Article	IF	CITATIONS
91	Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: Avoiding crystal growth using excipients. International Journal of Pharmaceutics, 2013, 454, 668-677.	5.2	43
92	Successful factorial design for the optimization of methylprednisolone encapsulation in biodegradable nanoparticles. Drug Development and Industrial Pharmacy, 2013, 39, 310-320.	2.0	13
93	Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1396-1404.	2.6	65
94	Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. International Journal of Pharmaceutics, 2013, 454, 686-694.	5.2	103
95	Nanomaterials: Applications in Drug Delivery. , 2013, , 131-151.		1
96	Lipid-Based Nanovectors for Targeting of CD44-Overexpressing Tumor Cells. Journal of Drug Delivery, 2013, 2013, 1-8.	2.5	48
97	Calixarene Cleansing Formulation for Uranium Skin Contamination. Health Physics, 2013, 105, 382-389.	0.5	12
98	Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique. International Journal of Nanomedicine, 2013, 8, 2065.	6.7	8
99	Role of thermal and mechanical effects on drug release from thermosensitive nanocarriers. , 2012, , .		3
100	Targeted Delivery Using Biodegradable Polymeric Nanoparticles. , 2012, , 255-288.		6
101	Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor. Journal of Controlled Release, 2012, 162, 545-552.	9.9	95
102	Aerosolized liposomal amphotericin B: Prediction of lung deposition, in vitro uptake and cytotoxicity. International Journal of Pharmaceutics, 2012, 436, 106-110.	5.2	26
103	Relaxation dynamics in single polymer microcapsules probed with laser-generated GHz acoustic waves. Soft Matter, 2012, 8, 2586.	2.7	20
104	Electrophoretic mobility measurement by laser Doppler velocimetry and capillary electrophoresis of micrometric fluorescent polystyrene beads. Analytical Methods, 2012, 4, 183-189.	2.7	5
105	Decorporation Approach Following Rat Lung Contamination with a Moderately Soluble Compound of Plutonium Using Local and Systemic Ca-DTPA Combined Chelation. Radiation Research, 2012, 178, 217-223.	1.5	17
106	Near infrared labeling of PLGA for in vivo imaging of nanoparticles. Polymer Chemistry, 2012, 3, 694.	3.9	39
107	Targeted nanotheranostics for personalized cancer therapy. Expert Opinion on Drug Delivery, 2012, 9, 1475-1487.	5.0	31
108	Novel Surfactants with Diglutamic Acid Polar Head Group: Drug Solubilization and Toxicity Studies. Pharmaceutical Research, 2012, 29, 1882-1896.	3.5	11

#	Article	IF	CITATIONS
109	Drug solubilization and in vitro toxicity evaluation of lipoamino acid surfactants. International Journal of Pharmaceutics, 2012, 423, 312-320.	5.2	39
110	Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19FMRI. Biomaterials, 2012, 33, 5593-5602.	11.4	69
111	Liposomes for intravitreal drug delivery: A state of the art. Journal of Controlled Release, 2012, 161, 628-634.	9.9	189
112	Spray-dried chitosan-metal microparticles for ciprofloxacin adsorption: Kinetic and equilibrium studies. Soft Matter, 2011, 7, 7304.	2.7	29
113	Biodegradable Nanoparticles Meet the Bronchial Airway Barrier: How Surface Properties Affect Their Interaction with Mucus and Epithelial Cells. Biomacromolecules, 2011, 12, 4136-4143.	5.4	91
114	Ex vivo decrease in uranium diffusion through intact and excoriated pig ear skin by a calixarene nanoemulsion. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 258-267.	4.3	24
115	Encapsulation of Cwp84 into pectin beads for oral vaccination against Clostridium difficile. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 566-573.	4.3	45
116	Nanoparticles: heating tumors to death?. Nanomedicine, 2011, 6, 99-109.	3.3	29
117	Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. International Journal of Nanomedicine, 2011, 6, 2591.	6.7	108
118	Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. Journal of Controlled Release, 2011, 152, 370-375.	9.9	44
119	Physicochemical characterization and toxicity evaluation of steroid-based surfactants designed for solubilization of poorly soluble drugs. European Journal of Pharmaceutical Sciences, 2011, 44, 595-601.	4.0	9
120	Comparison of the acoustic response of liquid-PFOB and solid-core nanoparticles between 20 and 40 MHz. , 2011, , .		0
121	STRUCTURE OF A SINGLE MODEL TO DESCRIBE PLUTONIUM AND AMERICIUM DECORPORATION BY DTPA TREATMENTS. Health Physics, 2010, 99, 553-559.	0.5	24
122	A NEW FORMULATION CONTAINING CALIXARENE MOLECULES AS AN EMERGENCY TREATMENT OF URANIUM SKIN CONTAMINATION. Health Physics, 2010, 99, 430-434.	0.5	19
123	Quick and efficient extraction of uranium from a contaminated solution by a calixarene nanoemulsion. International Journal of Pharmaceutics, 2010, 398, 179-184.	5.2	19
124	The performance of PEGylated nanocapsules of perfluorooctyl bromide as an ultrasound contrast agent. Biomaterials, 2010, 31, 1723-1731.	11.4	95
125	Liquid Perfluorocarbons as Contrast Agents for Ultrasonography and 19F-MRI. Pharmaceutical Research, 2010, 27, 1-16.	3.5	133
126	Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. European Journal of Pharmaceutical Sciences, 2010, 41, 281-288.	4.0	47

#	Article	IF	CITATIONS
127	Calixareneâ€Entrapped Nanoemulsion for Uranium Extraction from Contaminated Solutions. Journal of Pharmaceutical Sciences, 2010, 99, 1375-1383.	3.3	26
128	A new paradigm for high-sensitivity ¹⁹ F magnetic resonance imaging of perfluorooctylbromide. Magnetic Resonance in Medicine, 2010, 63, 1119-1124.	3.0	53
129	Nonlinear, detection of biodegradable, experimental nanoparticles using a high frequency ultrasound prototype. , 2010, , .		0
130	Mechanisms of antibiotic resistance and delivery strategies to prevent its emergence. Journal of Drug Delivery Science and Technology, 2010, 20, 407-418.	3.0	8
131	Preferential Decorporation of Americium by Pulmonary Administration of DTPA Dry Powder after Inhalation of Aged PuO ₂ Containing Americium in Rats. Radiation Research, 2010, 174, 637-644.	1.5	22
132	Modélisation de la décorporation du Pu/am par le dtpa. Radioprotection, 2009, 44, 431-446.	1.0	0
133	Formulation of glycerolipidic prodrugs into PEGylated liposomes for brain delivery. Journal of Drug Delivery Science and Technology, 2009, 19, 61-66.	3.0	2
134	Phospholipid decoration of microcapsules containing perfluorooctyl bromide used as ultrasound contrast agents. Biomaterials, 2009, 30, 1462-1472.	11.4	40
135	Removal of ciprofloxacin in simulated digestive media by activated charcoal entrapped within zinc-pectinate beads. International Journal of Pharmaceutics, 2009, 379, 251-259.	5.2	22
136	Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. British Journal of Pharmacology, 2009, 157, 179-194.	5.4	97
137	Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium after Systemic, Liver or Pulmonary Contamination of Rats Associated with Ca-DTPA Treatments. Radiation Research, 2009, 171, 674-686.	1.5	19
138	Hyaluronic Acid-Modified DOTAP/DOPE Liposomes for the Targeted Delivery of Anti-Telomerase siRNA to CD44-Expressing Lung Cancer Cells. Oligonucleotides, 2009, 19, 103-116.	2.7	90
139	Tuning microcapsules surface morphology using blends of homo- and copolymers of PLGA and PLGA-PEG. Soft Matter, 2009, 5, 3054.	2.7	45
140	Lipoplexes Targeting the CD44 Hyaluronic Acid Receptor for Efficient Transfection of Breast Cancer Cells. Molecular Pharmaceutics, 2009, 6, 1062-1073.	4.6	139
141	Colonic Delivery of Î²â€Łactamases Does not Affect Amoxicillin Pharmacokinetics in Rats. Journal of Pharmaceutical Sciences, 2008, 97, 1853-1863.	3.3	20
142	Perfluorooctyl Bromide Polymeric Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance Imaging. Advanced Functional Materials, 2008, 18, 2963-2971.	14.9	114
143	Surfactant dependent morphology of polymeric capsules of perfluorooctyl bromide: Influence of polymer adsorption at the dichloromethane–water interface. Journal of Colloid and Interface Science, 2008, 326, 66-71.	9.4	66
144	Quantification of pegylated phospholipids decorating polymeric microcapsules of perfluorooctyl bromide by reverse phase HPLC with a charged aerosol detector. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 702-707.	2.8	35

#	Article	IF	CITATIONS
145	State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. International Journal of Pharmaceutics, 2008, 364, 237-248.	5.2	107
146	Monitoring the buckling threshold of drying colloidal droplets using water-ethanol mixtures. European Physical Journal E, 2008, 27, 213-9.	1.6	16
147	Morphology, structure and supramolecular organization of hybrid 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine–hyaluronic acid microparticles prepared by spray drying. European Journal of Pharmaceutical Sciences, 2008, 34, 12-21.	4.0	28
148	Dexamethasone acetate encapsulation into Trojan particles. Journal of Controlled Release, 2008, 128, 41-49.	9.9	82
149	Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-ήB into activated macrophages. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 7-18.	4.3	29
150	Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 98-108.	4.3	45
151	Supramolecular organization and release properties of phospholipid-hyaluronan microparticles encapsulating dexamethasone. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 116-126.	4.3	21
152	Polymeric Nano- and Microparticles for the Delivery of Antisense Oligonucleotides and siRNA. , 2008, ,		1
153	Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms. Radiation Protection Dosimetry, 2007, 127, 472-476.	0.8	13
154	Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine, 2007, 25, 3946-3954.	3.8	73
155	Downregulation of Endotoxin-Induced Uveitis by Intravitreal Injection of Vasoactive Intestinal Peptide Encapsulated in Liposomes. , 2007, 48, 3230.		73
156	Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. International Journal of Pharmaceutics, 2007, 331, 153-159.	5.2	223
157	Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: Effect on lung and systemic decorporation of plutonium. Journal of Controlled Release, 2007, 118, 78-86.	9.9	66
158	Polymeric Nano/Microcapsules of Liquid Perfluorocarbons for Ultrasonic Imaging:Â Physical Characterization. Langmuir, 2006, 22, 4397-4402.	3.5	155
159	Evaluation of critical formulation parameters influencing the bioactivity of β-lactamases entrapped in pectin beads. International Journal of Pharmaceutics, 2006, 324, 2-9.	5.2	62
160	Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Advanced Drug Delivery Reviews, 2006, 58, 1203-1223.	13.7	126
161	Predicting Plutonium Decorporation Efficacy after Intravenous Administration of DTPA Formulations: Study of Pharmacokinetic–Pharmacodynamic Relationships in Rats. Pharmaceutical Research, 2006, 23, 2030-2035.	3.5	19
162	Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGFÎ ² -2 Therapy. Pharmaceutical Research, 2006, 23, 770-781.	3.5	48

#	Article	IF	CITATIONS
163	Sustained release of nanosized complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. Journal of Controlled Release, 2006, 112, 369-381.	9.9	93
164	Microencapsulation of Nanoparticulate Complexes of DNA with Cationic Lipids and Polymers in Pectin Beads for Targeted Gene Delivery. Nanobiotechnology, 2005, 1, 071-082.	1.2	5
165	Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation. Journal of Controlled Release, 2005, 110, 177-188.	9.9	41
166	Onset of Buckling in Drying Droplets of Colloidal Suspensions. Physical Review Letters, 2005, 94, 018302.	7.8	274
167	In vitroandin vivoevaluation of pectin beads for the colon delivery of β-lactamases. Journal of Drug Targeting, 2005, 13, 277-284.	4.4	33
168	Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 111-121.	2.5	49
169	Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 61, 1-13.	4.3	149
170	Polymer Colon Drug Delivery Systems and their Application to Peptides, Proteins, and Nucleic Acids. American Journal of Drug Delivery, 2005, 3, 171-204.	0.6	39
171	"Smart―delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Advanced Drug Delivery Reviews, 2004, 56, 931-946.	13.7	201
172	Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opinion on Drug Delivery, 2004, 1, 141-163.	5.0	146
173	Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis, 2003, 83, 379-385.	1.9	68
174	A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. International Journal of Pharmaceutics, 2003, 254, 89-93.	5.2	49
175	Long-Term Release and Improved Intracellular Penetration of Oligonucleotideâ^'Polyethylenimine Complexes Entrapped in Biodegradable Microspheres. Biomacromolecules, 2003, 4, 529-536.	5.4	48
176	Modification of the Elastic Constants of a Peptide-Decorated Lamellar Phase. Langmuir, 2002, 18, 4384-4392.	3.5	13
177	Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12001-12005.	7.1	475
178	Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. Journal of Pharmaceutical Sciences, 2002, 91, 790-799.	3.3	61
179	Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Investigative Ophthalmology and Visual Science, 2002, 43, 253-9.	3.3	62
180	Self Diffusion and Spectral Modifications of a Membrane Protein, the Rubrivivax gelatinosus LH2 Complex, Incorporated into a Monoolein Cubic Phase. Biophysical Journal, 2001, 81, 1613-1623.	0.5	15

#	Article	IF	CITATIONS
181	Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research, 2001, 18, 1157-1166.	3.5	405
182	Dramatic rigidification of a peptide-decorated lamellar phase. Physical Review E, 2001, 63, 041903.	2.1	13
183	Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharmaceutical Research, 2000, 17, 707-714.	3.5	149
184	Modification of Elastic Constants by Charge Addition to a Nonionic Lamellar Phase. Langmuir, 2000, 16, 2968-2974.	3.5	9
185	Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharmaceutical Research, 1998, 15, 1364-1369.	3.5	102
186	Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials, 1997, 18, 511-517.	11.4	67
187	Influence of surface properties on the inflammatory response to polymeric nanoparticles. Pharmaceutical Research, 1995, 12, 1385-1387.	3.5	13
188	A Novel Alternative for the Treatment of Diabetic Foot Wounds: A Three Dimensional Porous Dermal Matrix. , 0, , .		0